<DOC>
	<DOCNO>NCT01539616</DOCNO>
	<brief_summary>ZYH7 , novel peroxisome proliferator-activated receptor ( PPAR ) alpha agonist , expect decrease triglyceride level also correct dyslipidemia .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Safety Efficacy ZYH7 Compared Fenofibrate Patients With Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>1 . Age 1865 year 2 . Subjects either gender , male females 3 . Triglycerides 200 500 mg/dl screen visit . 4 . Body mass index ( BMI ) &gt; 23 kg/m2 5 . If subject diabetic , control maximum two oral anti diabetic agent except Thiazolidinedione . 6 . Subject give informed consent participation trial . 1 . Pregnancy lactation . 2 . History 5 % weight loss past 6 month . 3 . Subjects treatment insulin PPAR alpha gamma agonist past 3 month . 4 . Subjects unstable angina , acute myocardial infarction past 3 month heart failure New York Heart Association ( NYHA ) class ( IIIIV ) . 5 . Uncontrolled hypertension ( 150/100 mm Hg ) . ( If Subject use Thiazides , ACE inhibitor , beta blocker minimum 3 month stable therapy treatment expect change trial participation ) 6 . History clinically significant edema . 7 . History pancreatitis gall stone diseases . 8 . Subject thyroidstimulating hormone ( TSH ) level outside normal reference range , Subjects clinically euthyroid stable thyroid replacement therapy 2 month prior screen anticipate remain dose throughout trial period allow . 9 . Uncontrolled diabetes ( HbA1c ≥ 9 gm % ) . 10 . History active liver disease hepatic dysfunction demonstrate aspartate aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) ≥ 2.5 time upper normal limit ( UNL ) bilirubin ≥ 2 time UNL past 3 month . 11 . Renal dysfunction demonstrate abnormal Glomerular Filtration Rate ( GFR ) ( 60 ml/min ) presence ketonuria . 12 . History myopathy evidence active muscle disease demonstrate Creatinine Phosphokinase ( CPK ) ≥ 10 time UNL . 13 . History concurrent serious illness ( e.g . tuberculosis , Human Immunodeficiency Virus ( HIV ) infection , malignancy , etc ) . 14 . History alcohol and/or drug abuse . 15 . History known allergy , sensitivity intolerance study drug formulation ingredient . 16 . Subjects lipid lower medication . ( Appendix I ) . 17 . If contraceptive hormone replacement therapy ( HRT ) , therapy start change last 3 month . 18 . Prolonged use steroid ( 15 day ) last 3 month ( topical preparation , nasal intraarticular administration permit ) . 19 . History long term use nonsteroidal antiinflammatory drug . ( 1 month ) 20 . Participation clinical trial past 3 month 21 . Unable give inform consent follow protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Dyslipidemia</keyword>
</DOC>